{
    "nctId": "NCT05053841",
    "briefTitle": "Implication of Metformin Plus Aromatase Inhibitor in Obese Postmenopausal Breast Cancer Women",
    "officialTitle": "Implication of Combined Adjuvant Metformin and Aromatase Inhibitor in Overweight or Obese Postmenopausal Breast Cancer Women",
    "overallStatus": "COMPLETED",
    "conditions": "Metformin, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "change in serum level of the study biomarkers after treatment when compared with baseline values",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women, postmenopausal is defined either by:\n\nA. Age \u2265 55 years and one year or more of amenorrhea. B. Age \\< 55 years and one year or more of amenorrhea, with an estradiol assay \\< 20 pg/ml.\n\n\u2022 Patients with breast cancer indicated for hormonal treatment with aromatase inhibitors (overweight 30 \\> BMI \u2265 25, obese BMI \u2265 30 kg/m2 and non obese BMI between 18 and 25 kg/m2).\n\nExclusion Criteria:\n\n* \u2022 Diabetic patients.\n\n  * Patients with metabolic syndrome.\n  * Patients with last menstrual cycle less than one year ago.\n  * Patient with conditions predispose to acidosis (heart failure, renal failure).\n  * Ovarian radiation treatment with luteinizing hormone-releasing hormone (LH-RH) agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian suppression.",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}